ALK1/VEGF Combo Active in Advanced RCC
An early study looking at the combination of the ALK1 inhibitor dalantercept plus axitinib showed clinical activity in patients with advanced renal cell carcinoma.
Sorafenib Dose Escalation Not Supported in Most Untreated RCC Patients
Although the use of sorafenib in patients with treatment-naive metastatic renal cell carcinoma demonstrated clinical benefit, a phase IIb study did not support the use of dose escalation in these patients.
Everolimus, CB-839 Combination Active in Advanced RCC
The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.
Kidney Cancer Highlights of 2016
This slideshow takes a look at some of the top kidney cancer news of 2016, including FDA approvals, survival disparities, surgical approaches, and more.
Early Intervention Important for Sunitinib-Related Hypertension in RCC
Patients with metastatic renal cell carcinoma treated with sunitinib often experience treatment-related hypertension and require rigorous blood pressure control.
Non-Aspirin NSAID Use Associated With Shorter Survival in Metastatic RCC
Metastatic renal cell carcinoma (mRCC) patients who use non-aspirin NSAIDs have poorer overall survival than aspirin users and NSAID non-users, according to a new pooled retrospective analysis.
Acid Reducers Do Not Impact VEGF Inhibitor Efficacy in Metastatic RCC
The use of proton pump inhibitors does not appear to impact the efficacy of oral VEGF tyrosine kinase inhibitors in metastatic renal cell carcinoma, according to a new study.
Oncology Drug Snapshot: Axitinib (Inlyta)
This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Kidney Cancer Pathology
This kidney cancer slide show features images of chromophobe, papillary, and clear-cell renal cell carcinomas; as well as sarcomatoid, transitional cell, and small-cell carcinomas of the kidney.
By clicking Accept, you agree to become a member of the UBM Medica Community.